Luis E Echeverría1,2,3, Lyda Z Rojas2,4,5, María C Villamizar3, Carlos Luengas3, Angel M Chaves3, Jaime A Rodríguez1,3, Rafael Campo3, Claudia Clavijo3, Adriana M Redondo1, Luis A López6, Sergio Alejandro Gómez-Ochoa2, Carlos A Morillo7,8, Oscar L Rueda-Ochoa5,9, Oscar H Franco5,10. 1. Heart Failure and Transplant Clinic, Cardiovascular Foundation of Colombia, Floridablanca, Colombia. 2. Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, Colombia. 3. Non-invasive Cardiovascular Diagnostic, Cardiovascular Foundation of Colombia, Floridablanca, Colombia. 4. Department of Paediatrics, Obstetrics, Gynaecology and Preventative, Universidad Autònoma de Barcelona, Barcelona, Spain. 5. Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 6. Research Group and Development of Nursing Knowledge (GIDCEN-FCV), Research Institute, Cardiovascular Foundation of Colombia, Floridablanca, Colombia. 7. Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada. 8. Department of Medicine, Cardiology Division, McMaster University, PHRI-HHSC, Hamilton, ON, Canada. 9. Electrocardiography Research Group, Medicine School, Universidad Industrial de Santander, Bucaramanga, Colombia. 10. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Abstract
BACKGROUND: Chronic Chagas cardiomyopathy (CCM) is characterized by a unique type of cardiac involvement. Few studies have characterized echocardiographic (Echo) transitions from the indeterminate Chagas disease (ChD) form to CCM. The objective of this study was to identify the best cutoffs in multiple Echo parameters, speckle tracking, and N-terminal pro B-type natriuretic peptide (NT-proBNP) to distinguish patients without CCM (stage A) vs patients with myocardial involvement (stages B, C, or D). METHODS: Cross-sectional study conducted in 273 consecutive patients with different CCM stages. Echo parameters, NT-proBNP, and other clinical variables were measured. Logistic regression models (dichotomized in stage A versus B, C, and D) adjusted for age, sex, body mass index, and NT-proBNP were performed. RESULTS: Left ventricular global longitudinal strain (LV-GLS), mitral flow E velocity, LV mass index, and NT-proBNP identified early changes that differentiated stages A vs B, C, and D. The LV-GLS with a cutoff -20.5% showed the highest performance (AUC 92.99%; accuracy 84.56% and negative predictive value (NPV) 88.82%), which improved when it was additionally adjusted by NT-proBNP with a cutoff -20.0% (AUC 94.30%; accuracy 88.42% and NPV 93.55%). CONCLUSIONS: Our findings suggest that Echo parameters and NT-proBNP may be used as diagnostic variables in detecting the onset of myocardial alterations in patients with the indeterminate stage of ChD. LV-GLS was the more accurate measurement regarding stage A differentiation from the stages B, C, and D. Prospective longitudinal studies are needed to validate these findings.
BACKGROUND: Chronic Chagas cardiomyopathy (CCM) is characterized by a unique type of cardiac involvement. Few studies have characterized echocardiographic (Echo) transitions from the indeterminate Chagas disease (ChD) form to CCM. The objective of this study was to identify the best cutoffs in multiple Echo parameters, speckle tracking, and N-terminal pro B-type natriuretic peptide (NT-proBNP) to distinguish patients without CCM (stage A) vs patients with myocardial involvement (stages B, C, or D). METHODS: Cross-sectional study conducted in 273 consecutive patients with different CCM stages. Echo parameters, NT-proBNP, and other clinical variables were measured. Logistic regression models (dichotomized in stage A versus B, C, and D) adjusted for age, sex, body mass index, and NT-proBNP were performed. RESULTS: Left ventricular global longitudinal strain (LV-GLS), mitral flow E velocity, LV mass index, and NT-proBNP identified early changes that differentiated stages A vs B, C, and D. The LV-GLS with a cutoff -20.5% showed the highest performance (AUC 92.99%; accuracy 84.56% and negative predictive value (NPV) 88.82%), which improved when it was additionally adjusted by NT-proBNP with a cutoff -20.0% (AUC 94.30%; accuracy 88.42% and NPV 93.55%). CONCLUSIONS: Our findings suggest that Echo parameters and NT-proBNP may be used as diagnostic variables in detecting the onset of myocardial alterations in patients with the indeterminate stage of ChD. LV-GLS was the more accurate measurement regarding stage A differentiation from the stages B, C, and D. Prospective longitudinal studies are needed to validate these findings.
Authors: Minna Moreira Dias Romano; Henrique Turin Moreira; José Antônio Marin-Neto; Priscila Elias Baccelli; Fawaz Alenezi; Igor Klem; Benedito Carlos Maciel; Joseph Kisslo; André Schmidt; Eric J Velazquez Journal: PLoS Negl Trop Dis Date: 2020-11-30